AstraZenega's diabetes drug Farxiga reduces the risk of heart failure

announced that its phase III DAPA-HF clinical trial of dapagliozin had reached the primary endpoint of reducing cardiovascular death or worsening heart failure compared to a placebo. Farxiga is a state-of-the-art oral SGLT2 inhibitor approved as a monotherapy and a comprehensive therapy to improve blood sugar control in people with type 2 diabetes. In this trial, however, the drug successfully reduced the risk of heart attack or disease progression in patients with common types of heart failure. The patient's blood test score (HFrEF) was reduced and he was receiving standard treatment. About 40 percent of the patients in the trial also had type 2 diabetes, which is common in patients with heart failure.
“ Through the DAPA-HF trial, Farxiga became the first of its kind to demonstrate efficacy and safety data for treating patients with heart failure, whether or not they have type 2 diabetes, based on standard care," said Mene Pangalos, Executive Vice President of Research and Development at AstraZeneca Biopharmaceuticals. We look forward to discussing the results of DAPA-HF with global health authorities as soon as possible.
the U.S. Food and Drug Administration (FDA) earlier rejected Farxiga as a supplement to insulin in adults with type 1 diabetes because insulin alone does not control blood sugar levels.
Farxiga's competitors on these diabetes drugs include Lilly and Blinger Ingham's jardince, but so far it has not shown any benefits for heart failure patients. Another drug in this category, Johnson and Johnson's Invokana (canagliflozin), has a black box warning for lower limb amputations.
Analysts at Liberum noted that "this (results) will make the drug widely applicable and its effectiveness strongly validated, especially in people with diabetes." The results will also strengthen Farxiga's diabetes effect when oral GLP-1 is likely to enter the market.
and Glp-1 are another type of type 2 diabetes drug, such as semaglutide and vitoza (lilaglutide), Lilly's special effects drug (dulaglutide) and AstraZeneta's exenatide. GLP-1 similars stimulate the pancreas to produce insulin. They also reduce appetite by slowing the emptying of the stomach, which can lead to weight loss.
Farxiga is a SGLT2 inhibitor that allows the kidneys to drain blood sugar from the body through urine.
"The DAPA-HF study is considered an 'ace' by the market and has a low probability of success, and today is the first time that three studies have reported that sglt-2 has heart failure benefits for non-diabetic patients," JPMorgan analysts wrote in a note to clients. The
Farxiga research and development program includes 35 completed and ongoing phase iib/iii clinical trials involving more than 35,000 patients. In the delivery and determination (hfref and hfpef) trials, patients with heart failure retained by the shot fraction (hfpef) were also evaluated.
“ "We hope that these exciting new findings will ultimately help reduce the burden of heart failure-related diseases and help improve patient outcomes," said John McMurray of the Cardiovascular Research Centre at the University of Glasgow's Centre for Cardiovascular and Medical Sciences. ”（cyy123.com）